Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients.
Tsuruga T, Fujimoto A, Kawana K, Mori M, Hasumi Y, Kino N, Tomio K, Miura S, Tanikawa M, Sone K, Miyamoto Y, Ikeda Y, Kojima S, Adachi K, Nagasaka K, Matsumoto Y, Arimoto T, Oda K, Nakagawa S, Horie K, Yasugi T, Yokota H, Osuga Y, Fujii T. Tsuruga T, et al. Among authors: yokota h. Int J Clin Oncol. 2016 Apr;21(2):359-366. doi: 10.1007/s10147-015-0907-3. Epub 2015 Oct 5. Int J Clin Oncol. 2016. PMID: 26438230
Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.
Takano M, Kato M, Yoshikawa T, Sasaki N, Hirata J, Furuya K, Takahashi M, Yokota H, Kino N, Horie K, Goto T, Fujiwara K, Ishii K, Kikuchi Y, Kita T. Takano M, et al. Among authors: yokota h. Oncology. 2009;76(5):315-21. doi: 10.1159/000209335. Epub 2009 Mar 20. Oncology. 2009. PMID: 19299905
Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.
Shigeta S, Shimada M, Tsuji K, Nagai T, Tanase Y, Matsuo K, Kamiura S, Iwata T, Yokota H, Mikami M. Shigeta S, et al. Among authors: yokota h. Int J Clin Oncol. 2022 Sep;27(9):1507-1515. doi: 10.1007/s10147-022-02198-6. Epub 2022 Jun 14. Int J Clin Oncol. 2022. PMID: 35701640
Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).
Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; Gynecologic Oncology Study Group of the Japan Clinical Oncology Group. Kato T, et al. Among authors: yokota h. Gynecol Oncol. 2015 Apr;137(1):34-9. doi: 10.1016/j.ygyno.2015.01.548. Epub 2015 Feb 7. Gynecol Oncol. 2015. PMID: 25662625
Correction to: Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group.
Shigeta S, Shimada M, Tsuji K, Nagai T, Tanase Y, Matsuo K, Kamiura S, Iwata T, Yokota H, Mikami M. Shigeta S, et al. Among authors: yokota h. Int J Clin Oncol. 2022 Sep;27(9):1516. doi: 10.1007/s10147-022-02211-y. Int J Clin Oncol. 2022. PMID: 35819655 No abstract available.
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
Matoda M, Takeshima N, Michimae H, Iwata T, Yokota H, Torii Y, Yamamoto Y, Takehara K, Nishio S, Takano H, Mizuno M, Takahashi Y, Takei Y, Hasegawa T, Mikami M, Enomoto T, Aoki D, Sugiyama T. Matoda M, et al. Among authors: yokota h. Gynecol Oncol. 2018 Jun;149(3):513-519. doi: 10.1016/j.ygyno.2018.04.009. Epub 2018 Apr 13. Gynecol Oncol. 2018. PMID: 29661497 Clinical Trial.
1,479 results